scholarly article | Q13442814 |
review article | Q7318358 |
P2093 | author name string | Yunguang Tong | |
Jimin Liang | |||
Cuiqi Zhou | |||
Vladimir A Ljubimov | |||
Zhen Qin | |||
P2860 | cites work | Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing | Q46302330 |
Size distributions of maternal and fetal DNA in maternal plasma. | Q47432593 | ||
Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls | Q47831743 | ||
Digital karyotyping | Q22066241 | ||
Cancer genome landscapes | Q22242276 | ||
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients | Q24561669 | ||
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | Q24563539 | ||
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations | Q24678861 | ||
Digital PCR | Q24685020 | ||
Liquid biopsies: genotyping circulating tumor DNA | Q27010159 | ||
Evolution of the cancer genome | Q27020991 | ||
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
Methylation of cell-free circulating DNA in the diagnosis of cancer | Q28085699 | ||
Quantitative and sensitive detection of rare mutations using droplet-based microfluidics | Q28238121 | ||
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA | Q28239638 | ||
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number | Q28251729 | ||
Development of personalized tumor biomarkers using massively parallel sequencing | Q28278819 | ||
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing | Q28280303 | ||
Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers | Q28484970 | ||
Winnowing DNA for rare sequences: highly specific sequence and methylation based enrichment | Q28732084 | ||
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
Tumor metastasis: molecular insights and evolving paradigms | Q29615908 | ||
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
Detection and quantification of rare mutations with massively parallel sequencing | Q30472217 | ||
The origin of elevated levels of circulating DNA in blood plasma of premature neonates | Q33374139 | ||
Identification of microbial DNA in human cancer | Q33441903 | ||
Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer | Q33507538 | ||
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
Tumor heterogeneity: causes and consequences | Q33624298 | ||
Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients | Q33743256 | ||
High fragmentation characterizes tumour-derived circulating DNA. | Q34016528 | ||
Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system | Q34086089 | ||
About the possible origin and mechanism of circulating DNA apoptosis and active DNA release | Q34100424 | ||
Detection and quantification of mutations in the plasma of patients with colorectal tumors | Q34132363 | ||
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. | Q34139666 | ||
Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. | Q34207746 | ||
Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen | Q34211237 | ||
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. | Q34317490 | ||
High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. | Q34340492 | ||
Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing | Q34382581 | ||
Rapid clearance of fetal DNA from maternal plasma | Q34388637 | ||
Microsatellite alterations in serum DNA of head and neck cancer patients | Q34394745 | ||
Multiparametric analysis of cell-free DNA in melanoma patients | Q34499759 | ||
Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats | Q34530414 | ||
Neoplastic characteristics of the DNA found in the plasma of cancer patients | Q34543792 | ||
Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. | Q50882453 | ||
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. | Q51752412 | ||
Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. | Q53534876 | ||
Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. | Q54714698 | ||
Increased plasma DNA integrity in cancer patients. | Q54763921 | ||
Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. | Q54769141 | ||
Free DNA in the serum of cancer patients and the effect of therapy. | Q55492005 | ||
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients | Q57240090 | ||
Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia | Q60305981 | ||
Changes in Concentration of DNA in Serum and Plasma during Storage of Blood Samples | Q62632521 | ||
Soluble normal and mutated DNA sequences from single-copy genes in human blood | Q72268467 | ||
The use of fluorometric assays to assess the immune response to DNA in murine systemic lupus erythematosus | Q73489250 | ||
The origin and mechanism of circulating DNA | Q73808680 | ||
Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells? | Q77170479 | ||
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients | Q77804773 | ||
Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma | Q77924833 | ||
Disappearance curves for tumor markers after resection of intrathoracic malignancies | Q77982209 | ||
Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer | Q82218655 | ||
Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease | Q84589922 | ||
Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression | Q87382252 | ||
Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma | Q38270678 | ||
Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma | Q38395321 | ||
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer | Q38418038 | ||
Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays | Q39922627 | ||
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade | Q42690704 | ||
Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma | Q43469202 | ||
Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. | Q43512551 | ||
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. | Q43540280 | ||
Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing | Q44576396 | ||
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer | Q44670943 | ||
Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma | Q45721923 | ||
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma | Q46062133 | ||
Detection of ultrarare somatic mutation in the human TP53 gene by bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification | Q46131826 | ||
??? | Q94720111 | ||
DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer | Q34555788 | ||
Prediction of breast tumor progression by integrity of free circulating DNA in serum. | Q34565015 | ||
Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? | Q34577740 | ||
If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells | Q34625589 | ||
Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum | Q35016114 | ||
Identification of an intracellular precursor to DNA excreted by human lymphocytes | Q35024389 | ||
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors | Q35132293 | ||
Tumor clone dynamics in lethal prostate cancer | Q35575930 | ||
Genomic analysis of circulating cell-free DNA infers breast cancer dormancy | Q35694373 | ||
Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus | Q35763885 | ||
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA | Q35810461 | ||
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer | Q35879064 | ||
Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients | Q35995428 | ||
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease | Q36000803 | ||
Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool | Q36372817 | ||
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood | Q36497457 | ||
Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients | Q36618056 | ||
Circulating nucleic acids (CNAs) and cancer--a survey | Q36669780 | ||
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance | Q36719984 | ||
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. | Q36998629 | ||
Detection, clinical relevance and specific biological properties of disseminating tumour cells | Q37135356 | ||
The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients | Q37225239 | ||
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy | Q37286893 | ||
Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer | Q37765189 | ||
Circulating tumour cells in cancer patients: challenges and perspectives | Q37776363 | ||
Cell-free DNA in the circulation as a potential cancer biomarker. | Q37903558 | ||
Overcoming implementation challenges of personalized cancer therapy | Q38031117 | ||
DNA methylation profiling in the clinic: applications and challenges | Q38040319 | ||
Circulating tumor cells: liquid biopsy of cancer | Q38046735 | ||
The implications of clonal genome evolution for cancer medicine | Q38085043 | ||
Circulating tumour cells and cell-free DNA as tools for managing breast cancer | Q38109808 | ||
Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. | Q38152782 | ||
Technologies for detection of circulating tumor cells: facts and vision | Q38154493 | ||
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance | Q38249332 | ||
Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? | Q38261856 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | neoplasm | Q1216998 |
tumor biomarker | Q66205818 | ||
neoplasm DNA | Q71515340 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | 36 | |
P577 | publication date | 2016-04-07 | |
P1433 | published in | Chinese Journal of Cancer | Q15760211 |
P1476 | title | Cell-free circulating tumor DNA in cancer | |
P478 | volume | 35 |